Abstract

Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other sources, systematic differences between different MR scanners are suspected to contribute to this variability. In this study we developed and performed initial validation tests of an MR-compatible phantom and analysis software for robust and reliable evaluation of the brain volume loss. The phantom contained three inflatable models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Software to reliably quantify volumes form the phantom images was also developed. To validate the method, the phantom was imaged using 3D T1-weighted protocols at three clinical 3T MR scanners from different vendors. Calculated volume change from MRI was compared with the known applied volume change using ICC and mean absolute difference. As assessed by the ICC, the agreement between our developed software and the applied volume change for different structures ranged from 0.999–1 for hemisphere, 0.976–0.998 for putamen, and 0.985–0.999 for caudate nucleus. The mean absolute differences between measured and applied volume change were 109–332 μL for hemisphere, 2.9–11.9 μL for putamen, and 2.2–10.1 μL for caudate nucleus. This method offers a reliable and robust measurement of volume change using MR images and could potentially be used to standardize clinical measurement of atrophy rates.
Original languageEnglish
Article number101667
JournalNeuroImage: Clinical
Volume21
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

@article{468b7622a8a64decac5a2f85e2a8f54c,
title = "Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI",
abstract = "Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other sources, systematic differences between different MR scanners are suspected to contribute to this variability. In this study we developed and performed initial validation tests of an MR-compatible phantom and analysis software for robust and reliable evaluation of the brain volume loss. The phantom contained three inflatable models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Software to reliably quantify volumes form the phantom images was also developed. To validate the method, the phantom was imaged using 3D T1-weighted protocols at three clinical 3T MR scanners from different vendors. Calculated volume change from MRI was compared with the known applied volume change using ICC and mean absolute difference. As assessed by the ICC, the agreement between our developed software and the applied volume change for different structures ranged from 0.999–1 for hemisphere, 0.976–0.998 for putamen, and 0.985–0.999 for caudate nucleus. The mean absolute differences between measured and applied volume change were 109–332 μL for hemisphere, 2.9–11.9 μL for putamen, and 2.2–10.1 μL for caudate nucleus. This method offers a reliable and robust measurement of volume change using MR images and could potentially be used to standardize clinical measurement of atrophy rates.",
author = "Houshang Amiri and Iman Brouwer and Kuijer, {Joost P. A.} and {de Munck}, {Jan C.} and Frederik Barkhof and Hugo Vrenken",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.nicl.2019.101667",
language = "English",
volume = "21",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI

AU - Amiri, Houshang

AU - Brouwer, Iman

AU - Kuijer, Joost P. A.

AU - de Munck, Jan C.

AU - Barkhof, Frederik

AU - Vrenken, Hugo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other sources, systematic differences between different MR scanners are suspected to contribute to this variability. In this study we developed and performed initial validation tests of an MR-compatible phantom and analysis software for robust and reliable evaluation of the brain volume loss. The phantom contained three inflatable models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Software to reliably quantify volumes form the phantom images was also developed. To validate the method, the phantom was imaged using 3D T1-weighted protocols at three clinical 3T MR scanners from different vendors. Calculated volume change from MRI was compared with the known applied volume change using ICC and mean absolute difference. As assessed by the ICC, the agreement between our developed software and the applied volume change for different structures ranged from 0.999–1 for hemisphere, 0.976–0.998 for putamen, and 0.985–0.999 for caudate nucleus. The mean absolute differences between measured and applied volume change were 109–332 μL for hemisphere, 2.9–11.9 μL for putamen, and 2.2–10.1 μL for caudate nucleus. This method offers a reliable and robust measurement of volume change using MR images and could potentially be used to standardize clinical measurement of atrophy rates.

AB - Brain volume loss, or atrophy, has been proven to be an important characteristic of neurological diseases such as Alzheimer's disease and multiple sclerosis. To use atrophy rate as a reliable clinical biomarker and to increase statistical power in clinical treatment trials, measurement variability needs to be minimized. Among other sources, systematic differences between different MR scanners are suspected to contribute to this variability. In this study we developed and performed initial validation tests of an MR-compatible phantom and analysis software for robust and reliable evaluation of the brain volume loss. The phantom contained three inflatable models of brain structures, i.e. cerebral hemisphere, putamen, and caudate nucleus. Software to reliably quantify volumes form the phantom images was also developed. To validate the method, the phantom was imaged using 3D T1-weighted protocols at three clinical 3T MR scanners from different vendors. Calculated volume change from MRI was compared with the known applied volume change using ICC and mean absolute difference. As assessed by the ICC, the agreement between our developed software and the applied volume change for different structures ranged from 0.999–1 for hemisphere, 0.976–0.998 for putamen, and 0.985–0.999 for caudate nucleus. The mean absolute differences between measured and applied volume change were 109–332 μL for hemisphere, 2.9–11.9 μL for putamen, and 2.2–10.1 μL for caudate nucleus. This method offers a reliable and robust measurement of volume change using MR images and could potentially be used to standardize clinical measurement of atrophy rates.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060111748&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30665101

U2 - 10.1016/j.nicl.2019.101667

DO - 10.1016/j.nicl.2019.101667

M3 - Article

VL - 21

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

M1 - 101667

ER -